Advagraf 3 mg Norge - norsk - Statens legemiddelverk

advagraf 3 mg

orifarm as - takrolimusmonohydrat - depotkapsel, hard - 3 mg

Tecfidera 240 mg Norge - norsk - Statens legemiddelverk

tecfidera 240 mg

2care4 aps - dimetylfumarat - enterokapsel, hard - 240 mg

Tecfidera 240 mg Norge - norsk - Statens legemiddelverk

tecfidera 240 mg

orifarm as - dimetylfumarat - enterokapsel, hard - 240 mg

Tecfidera 120 mg Norge - norsk - Statens legemiddelverk

tecfidera 120 mg

orifarm as - dimetylfumarat - enterokapsel, hard - 120 mg

Vumerity Den europeiske union - norsk - EMA (European Medicines Agency)

vumerity

biogen netherlands b.v. - diroximel fumarate (biib098) - multippel sklerose, relapsing-remitting - immunsuppressive - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).

Teriflunomide Mylan Den europeiske union - norsk - EMA (European Medicines Agency)

teriflunomide mylan

mylan pharmaceuticals limited - teriflunomide - multippel sklerose, relapsing-remitting - immunsuppressive - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Teriflunomide Accord Den europeiske union - norsk - EMA (European Medicines Agency)

teriflunomide accord

accord healthcare s.l.u. - teriflunomide - multippel sklerose, relapsing-remitting - immunosuppressants, selektiv immunosuppressants - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Bimzelx Den europeiske union - norsk - EMA (European Medicines Agency)

bimzelx

ucb pharma s.a.   - bimekizumab - psoriasis - immunsuppressive - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Prograf 0.5 mg Norge - norsk - Statens legemiddelverk

prograf 0.5 mg

orifarm as - takrolimus - kapsel, hard - 0.5 mg

Prograf 0.5 mg Norge - norsk - Statens legemiddelverk

prograf 0.5 mg

orifarm as - takrolimus - kapsel, hard - 0.5 mg